Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of CytRx Corporation and Advises Investors With Losses to Contact the Firm

Business Wire July 12, 2016

Mid-Afternoon Market Update: Dow Jumps 140 Points; Imperva Shares Slide Following Reduced Q2 Outlook

Benzinga.com  July 12, 2016

8 Biggest Mid-Day Losers For Tuesday

Benzinga.com  July 12, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by Certain Officers and Directors of CytRx Corporation

Business Wire July 12, 2016

Investor Alert: Investigation of CytRx Announced by Holzer & Holzer, LLC

Business Wire July 12, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  July 12, 2016

Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

Benzinga.com  July 12, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  July 12, 2016

Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx

PR Newswire June 17, 2016

CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting

PR Newswire June 6, 2016

CytRx to Present at Jefferies 2016 Global Healthcare Conference

PR Newswire May 31, 2016

CytRx Reports First Quarter 2016 Financial Results

PR Newswire May 11, 2016

CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference

PR Newswire April 28, 2016

CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year

PR Newswire April 25, 2016

CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016

PR Newswire April 20, 2016

CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

PR Newswire April 4, 2016

CytRx to Present New Data Using Its Proprietary LADR(TM) Technology at the 2016 American Association for Cancer Research Annual Meeting

PR Newswire March 22, 2016

CytRx Reports 2015 Financial Results

PR Newswire March 11, 2016

CytRx to Present at the Cowen & Company's 36th Annual Health Care Conference

PR Newswire February 29, 2016

CytRx Secures $40 Million Long-Term Loan Facility

PR Newswire February 8, 2016